1/13
07:17 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/13
05:46 am
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/13
05:11 am
mirm
3 Top Growth Stocks to Buy in the First Half of 2026 [Yahoo! Finance]
Low
Report
3 Top Growth Stocks to Buy in the First Half of 2026 [Yahoo! Finance]
1/12
05:30 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
01:06 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/12
11:37 am
mirm
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 [Yahoo! Finance]
Low
Report
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 [Yahoo! Finance]
1/12
08:30 am
mirm
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
Medium
Report
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
1/9
11:55 am
mirm
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
Low
Report
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
1/7
04:23 pm
mirm
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
04:01 pm
mirm
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/6
08:52 am
mirm
Should You Invest in Mirum Pharmaceuticals (MIRM)? [Yahoo! Finance]
Low
Report
Should You Invest in Mirum Pharmaceuticals (MIRM)? [Yahoo! Finance]
12/30
03:31 am
mirm
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now [Yahoo! Finance]
Low
Report
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now [Yahoo! Finance]
12/25
07:00 pm
mirm
What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now [Yahoo! Finance]
Low
Report
What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now [Yahoo! Finance]
12/22
03:49 pm
mirm
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So [Seeking Alpha]
12/22
03:33 pm
mirm
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 [Seeking Alpha]
Low
Report
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 [Seeking Alpha]
12/19
09:05 am
mirm
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX [Yahoo! Finance]
12/19
08:43 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $95.00 to $140.00. They now have a "market outperform" rating on the stock.
Medium
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $95.00 to $140.00. They now have a "market outperform" rating on the stock.
12/19
08:30 am
mirm
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
Medium
Report
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
12/19
06:09 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/16
12:45 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Stifel Nicolaus from $92.00 to $98.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Stifel Nicolaus from $92.00 to $98.00. They now have a "buy" rating on the stock.
12/11
09:04 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/11
05:42 am
mirm
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance]
12/10
07:00 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/10
05:04 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/10
05:03 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.